Drug intelligence / Profile preview

JNJ-38224342

Development stage: Phase 1
Lead developer: Johnson & Johnson
Modality: Small Molecules
Administration: Oral

Overview

JNJ-38224342 is an investigational oral agent developed by Johnson & Johnson Pharmaceutical Research & Development for the treatment of seasonal allergic rhinitis. The drug was evaluated in phase 1 clinical trials to assess its safety profile in both healthy volunteers and patients with seasonal allergies. Its precise mechanism of action has not been publicly disclosed, and there is no evidence it advanced beyond early-stage clinical development[1][2][3][4].

Targets

HRH4 (Histamine H4 receptor)

Beyond the preview

Go deeper on JNJ-38224342.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-38224342.

Explore the full profile